NCT04075422View on ClinicalTrials.gov

"Bezlotoxumab - in Real Life - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence."

CompletedOBSERVATIONAL

Enrollment

869

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

August 5, 2021

Study Completion Date

October 28, 2022

Conditions

Clostridium Difficile Infection

Interventions

DRUG

Bezlotoxumab Injection [Zinplava]

Treatment with bezlotoxumad according to the routine clinical practices

Trial Locations (6)

Unknown

Hospital Clinico San Carlos, Madrid

Hospital Fundacion de Alcorcón, Madrid

Hospital Gregorio Marañon, Madrid

Hospital Ramón y Cajal, Madrid

Hospital Univ. La Paz, Madrid

Hospital Univ. Puerta de HIerro, Madrid

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Fundacion SEIMC-GESIDA

OTHER

NCT04075422 - "Bezlotoxumab - in Real Life - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence." | Biotech Hunter | Biotech Hunter